Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-booster Study
NCT05809271Phase 1Completed
- Sponsor
- University Hospital Basel
- Start
- Nov 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of midomafetamine in post-traumatic stress disorder (PTSD) (3 arms), sponsored by University Hospital Basel. Primary endpoint: Subjective effect duration for 'any drug effect' at 9 hours. Started Nov 2023; status: completed.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05809271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05809271.